Cirrhosis

Cirrhosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising g protein coupled receptor 119 ...
May 25, 2017 - N°20170143714

Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a gpr119 ligand as an active ingredient. The composition comprising the gpr119 ligand as an active ingredient significantly inhibits the expression of collagen i, transforming growth factor β (tgfβ) and α-smooth muscle actin (α-sma), thereby inhibiting hsc activation, and also significantly ...
Formulations of l-ornithine phenylacetate
Ocera Therapeutics, Inc.
May 18, 2017 - N°20170135973

Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, ...
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of ...
Industry-academic Cooperation Foundation, Yonsei University
May 04, 2017 - N°20170121380

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of the complications of chronic liver disease with caspase inhibitors
Conatus Pharmaceuticals, Inc.
April 13, 2017 - N°20170100448

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
"methods for modeling hepatic inflammation"
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
March 23, 2017 - N°20170083683

Provided herein are in silico methods of modeling hepatic inflammation, fibrosis/cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer. The modeling system also is useful in modeling the effects of active agents on normal hepatic tissue or hepatic tissue perturbed by inflammation, ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
Centre Hospitalier Universitaire D'angers
March 16, 2017 - N°20170071968

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Ultrapure tetrahydrocannabinol-11-oic-acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071900

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Ultrapure tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071899

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Ultrapure tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071898

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
The Trustees Of The University Of Pennsylvania
February 23, 2017 - N°20170051259

Viral vectors comprising engineered hotc dna and rna sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hotc for treatment of liver fibrosis cirrhosis in otcd patients by administering hotc.
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
The Trustess Of The University Of Pennsylvania
January 26, 2017 - N°20170021037

Non-viral delivery systems comprising engineered hotc dna and rna sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hotc for treatment of liver fibrosis and/or cirrhosis in otcd patients by administering hotc.
Compositions and methods for treating renal failure
La Jolla Pharmaceutical Company
January 19, 2017 - N°20170014471

The present disclosure relates to the use of angiotensin ii in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals Inc.
December 22, 2016 - N°20160367518

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post ...
Nitrogenous heterocyclic derivatives and their application in drugs
Sunshine Lake Pharma Co., Ltd.
December 08, 2016 - N°20160355501

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially ...
Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
Sunshine Lake Pharma Co., Ltd.
December 08, 2016 - N°20160354387

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Formulations of l-ornithine phenylacetate
Ocera Therapeutics, Inc.
November 24, 2016 - N°20160338982

Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of preparing the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, ...
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
September 29, 2016 - N°20160279157

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Pharmaceutical composition for preventing or treating liver diseases, containing plasmalogen precursor, plasmalogen or plasmalogen analog ...
University Of Ulsan Foundation For Industry Cooper Ation
September 15, 2016 - N°20160263130

The present invention relates to a pharmaceutical composition for preventing or treating liver diseases, containing a plasmalogen precursor, plasmalogen, or a plasmalogen analog as an effective component. More specifically, a plasmalogen precursor, or plasmalogen or a plasmalogen analog produced by metabolizing the plasmalogen precursor, can prevent or treat liver diseases such as hepatic steatosis, hepatitis, or liver cirrhosis, etc. By ...
Compositions and methods comprising a defined microbiome and methods of use thereof
The Trustees Of The University Of Pennsylvania
August 25, 2016 - N°20160243175

The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.
Composition and methods for treating intestinal hyperpermeability
The Trustees Of The University Of Pennsylvania
August 18, 2016 - N°20160235701

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic ...